Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical Trial
- 31 May 2005
- journal article
- clinical trial
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 80 (5), 601-610
- https://doi.org/10.4065/80.5.601
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Human papillomavirus type specific DNA and RNA persistence—implications for cervical disease progression and monitoringJournal of Medical Virology, 2004
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Incidence, Prevalence, and Clearance of Type‐Specific Human Papillomavirus Infections: The Young Women’s Health StudyThe Journal of Infectious Diseases, 2002
- The causal relation between human papillomavirus and cervical cancerJournal of Clinical Pathology, 2002
- Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective studyThe Lancet, 1999
- Estimates of the Incidence and Prevalence of Sexually Transmitted Diseases in the United StatesSexually Transmitted Diseases, 1999
- Prevalence of Human Papillomavirus in Cervical Cancer: a Worldwide PerspectiveJNCI Journal of the National Cancer Institute, 1995
- Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.Proceedings of the National Academy of Sciences, 1992
- Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particlesVirology, 1991